Imbed Biosciences
Madison, US · Founded 2010 · Wisconsin corporation · 1 known investors
Find your way into Imbed Biosciences
349 people in our graph share verified history with the Imbed Biosciences team — schools, employers, funds. One of them is your warm intro.
Neeraj Aroraunlockedknows Ankit Agarwal · together at Indian Institute of Technology, Delhi (overlapped)
×2knows the team · via University of Wisconsin-Madison
×3knows the team · via Indian Institute of Technology, Delhi
×5knows the team · via Iowa State University
knows the team · via University of Adelaide
Imbed Biosciences is a medical device company that develops SAMatrix, an ultra-thin, fully synthetic bioresorbable wound matrix that integrates antimicrobial silver and non-opioid pain agents (lidocaine) for treating chronic and acute wounds such as ulcers, surgical, traumatic, and burn wounds. Its product portfolio includes Surgaflex, Pelashield, and Microlyte, along with PainGuard variants.
Founders & leadership
Imbed Biosciences was founded in 2010 by Nicholas L Abbott and Ankit Agarwal.
NL
Nicholas L AbbottinCo-FounderNicholas Abbott holds a B.S. in Chemical Engineering from the University of Adelaide and a Ph.D. in Chemical Engineering from MIT, with postdoctoral training at Harvard. He held faculty positions at UC Davis, University of Wisconsin-Madison (where he directed the Materials Research Science and Engineering Center), and joined Cornell University as Tisch University Professor of Chemical and Biomolecular Engineering in 2018. His research has resulted in over 500 peer-reviewed publications and 78 U.S. patents, and he is a member of the National Academy of Engineering and fellow of the AAAS and APS.
AA
Ankit AgarwalinFounder, CSO, Board DirectorAnkit Agarwal is founder and former CEO of Imbed Biosciences, a medical device company developing synthetic bioresorbable wound matrices with integrated antimicrobial and analgesic agents. He holds expertise in biomaterials and drug delivery, has secured $30M+ in venture financing and $15M+ in NIH/NSF/DOD small business grants, and is an inventor on over 25 patents.
Board
DG
David GuintherBoard director
RA
Robert A BeckmanBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$22.3M disclosed across 8 rounds · 2014–2023
▶$3.5MraisedDec 2023 · 1 investors · BiotechnologyRule 506(b)
▶$3.5MraisedDec 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Philip FosterDirector
- Ankit AgarwalExecutive Officer, Director
- Walter DeweyDirector
- David GuintherDirector
- Jonathan BlackDirector
- Elizabeth TaylorExecutive Officer
- Offering amount
- $3.6M
- Amount sold
- $3.5M
- First sale
- Dec 2023
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$2.5MraisedMay 2023 · 2 investors · BiotechnologyRule 506(b)
▶$2.5MraisedMay 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David GuintherDirector
- Jonathan BlackExecutive Officer, Director
- Ankit AgarwalExecutive Officer, Director
- Elizabeth TaylorExecutive Officer
- Walter DeweyDirector
- Philip FosterDirector
- Offering amount
- $6M
- Amount sold
- $2.5M
- Minimum investment
- $35K
- First sale
- May 2023
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$7.9MraisedNov 2021 · 37 investors · BiotechnologyRule 506(b)
▶$7.9MraisedNov 2021 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David GuintherDirector
- Jeff HansonDirector
- Michael J. SchurrDirector
- Elizabeth B. TaylorDirector
- Ankit AgarwalExecutive Officer, Director
- Offering amount
- $14.2M
- Amount sold
- $7.9M
- First sale
- Nov 2021
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$1.5MraisedJun 2020 · 18 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJun 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. SchurrDirector
- Ankit AgarwalExecutive Officer, Director
- David GuintherDirector
- Jeff HansonDirector
- Elizabeth B. TaylorDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Jun 2020
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$4MraisedOct 2019 · 47 investors · BiotechnologyRule 506(b)
▶$4MraisedOct 2019 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael SchurrDirector
- Elizabeth B. TaylorDirector
- David GuintherDirector
- Nicholas L AbbottExecutive Officer, Director
- Ankit AgarwalExecutive Officer, Director
- Robert A. BeckmanDirector
- Offering amount
- $4.1M
- Amount sold
- $4M
- First sale
- Oct 2018
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$1.6MraisedDec 2017 · 11 investors · BiotechnologyRule 506(b)
▶$1.6MraisedDec 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ankit AgarwalExecutive Officer, Director
- Robert A. BeckmanDirector
- Nicholas L AbbottExecutive Officer, Director
- David GuintherDirector
- Offering amount
- $1.7M
- Amount sold
- $1.6M
- First sale
- Dec 2017
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$600KraisedAug 2016 · 3 investors · BiotechnologyRule 506(b)
▶$600KraisedAug 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas L AbbottExecutive Officer, Director
- David GuintherDirector
- Robert A BeckmanDirector
- Ankit AgarwalExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $600K
- Minimum investment
- $25K
- First sale
- Aug 2016
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$683.3KraisedSep 2014 · 8 investors · BiotechnologyRule 506(b)
▶$683.3KraisedSep 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas L AbbottExecutive Officer, Director
- Ankit AgarwalExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $683.3K
- Minimum investment
- $25K
- First sale
- Apr 2014
- Incorporated
- Corporation, Wisconsin, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Imbed Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $806.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Science Foundation | Phase I | 2014 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $326.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Imbed Biosciences do?
- Imbed Biosciences is a medical device company that develops SAMatrix, an ultra-thin, fully synthetic bioresorbable wound matrix that integrates antimicrobial silver and non-opioid pain agents (lidocaine) for treating chronic and acute wounds such as ulcers, surgical, traumatic, and burn wounds. Its product portfolio includes Surgaflex, Pelashield, and Microlyte, along with PainGuard variants.
- Who founded Imbed Biosciences?
- Imbed Biosciences was founded by Nicholas L Abbott, Ankit Agarwal in 2010.
- Who are Imbed Biosciences's investors?
- Imbed Biosciences's investors include Wisconsin Investment Partners.
- How much funding has Imbed Biosciences raised?
- Imbed Biosciences has disclosed $22.3M raised across 8 rounds.
- Where is Imbed Biosciences headquartered?
- Imbed Biosciences is headquartered in Madison, US.